| __timestamp | Dynavax Technologies Corporation | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 22570000 |
| Thursday, January 1, 2015 | 22180000 | 24378000 |
| Friday, January 1, 2016 | 37257000 | 26621000 |
| Sunday, January 1, 2017 | 27367000 | 28653000 |
| Monday, January 1, 2018 | 64770000 | 37734000 |
| Tuesday, January 1, 2019 | 74986000 | 41884000 |
| Wednesday, January 1, 2020 | 79256000 | 64435000 |
| Friday, January 1, 2021 | 100156000 | 57483000 |
| Saturday, January 1, 2022 | 131408000 | 70062000 |
| Sunday, January 1, 2023 | 152946000 | 52790000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Ligand Pharmaceuticals Incorporated and Dynavax Technologies Corporation, from 2014 to 2023.
Over this period, Dynavax Technologies Corporation has seen a staggering 760% increase in SG&A expenses, peaking at approximately $153 million in 2023. This growth reflects the company's aggressive expansion and investment in administrative capabilities. In contrast, Ligand Pharmaceuticals Incorporated experienced a more modest 134% increase, reaching around $70 million in 2022, before a slight dip in 2023.
These trends highlight differing strategic approaches: Dynavax's rapid scaling versus Ligand's steady growth. Investors should consider these trajectories when evaluating potential opportunities in the biotech sector.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing MorphoSys AG and Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.